Lahjavida | Pipeline

pipeline & programs

Focused Innovation With a Clear Path to Clinic

Lahjavida Bio’s development strategy centers on disciplined execution — advancing our lead Dye-Drug Conjugate (DDC) toward IND readiness while unlocking the broader potential of our modular platform.

Lahjavida Bio is committed to advancing a first-in-class modality with the potential to transform how cancer therapies are delivered — beginning with our lead DDC and expanding thoughtfully across the solid-tumor landscape.

Lead DDC Program

Our lead DDC candidate is currently undergoing preclinical optimization, with upcoming studies focused on:

Tumor-selective uptake
Payload release
Safety to support IND-enabling activities

This program represents the first step in establishing a new small-molecule precision oncology modality with meaningful advantages over large-molecule ADCs.

Scalable Platform Expansion

In parallel, we are building a scalable pipeline of next-generation DDC constructs, each designed to validate:

Additional payload classes
Linker innovations
Tumor-targeting applications

Strategic Growth Path

As these programs mature, we will selectively pursue:

Partnerships to extend the platform into high-need oncology indications
Accelerate global development.

DDC Pipeline Overview

Compound	Dye	Linker	Payload
DDC1	Dye 1	Standard	SN38*
DDC2	Dye 2	Standard	SN38*
DDC3	Dye 1	Standard	MMAE**
DDC4	Dye 1	Standard	Doxorubicin***
DDC5	Dye 2	Standard	Doxorubicin***
DDC6	Dye 1	New	MMAE**

* SN38 is a *topoisomerase I inhibitor. It stabilizes the Topo I–DNA cleavage complex, leading to DNA breaks during replication and ultimately cell death.

** MMAE (monomethyl auristatin E) is a highly potent microtubule (tubulin) polymerization inhibitor that induces G2/M cell-cycle arrest and apoptosis by disrupting the mitotic spindle.

*** Doxorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, causing DNA breaks, and also generates free radicals that contribute to cytotoxicity.